Allspring Global Investments Holdings LLC Has $24.01 Million Position in Amgen Inc. $AMGN

Allspring Global Investments Holdings LLC cut its holdings in Amgen Inc. (NASDAQ:AMGN) by 3.4% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 67,956 shares of the medical research company’s stock after selling 2,397 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Amgen were worth $24,008,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of AMGN. Anfield Capital Management LLC increased its holdings in Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after purchasing an additional 70 shares in the last quarter. Dogwood Wealth Management LLC lifted its holdings in shares of Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 55 shares in the last quarter. Tower View Wealth Management LLC lifted its holdings in shares of Amgen by 331.6% in the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 63 shares in the last quarter. Manning & Napier Advisors LLC boosted its position in shares of Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after buying an additional 32 shares during the period. Finally, Olistico Wealth LLC acquired a new position in shares of Amgen during the fourth quarter worth about $33,000. 76.50% of the stock is owned by institutional investors.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.85% of the company’s stock.

Amgen Stock Performance

AMGN opened at $364.17 on Tuesday. The business’s 50-day simple moving average is $348.38 and its 200 day simple moving average is $350.78. Amgen Inc. has a 52-week low of $269.77 and a 52-week high of $391.29. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The firm has a market capitalization of $196.55 billion, a PE ratio of 25.34, a PEG ratio of 3.71 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same period last year, the company earned $4.90 earnings per share. The business’s revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, sell-side analysts expect that Amgen Inc. will post 22.31 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Weiss Ratings lowered Amgen from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, July 15th. UBS Group upped their price target on Amgen from $400.00 to $420.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Truist Financial raised their price target on shares of Amgen from $327.00 to $340.00 and gave the stock a “hold” rating in a research note on Tuesday, July 7th. BMO Capital Markets reiterated an “outperform” rating and issued a $400.00 price objective on shares of Amgen in a report on Wednesday, July 1st. Finally, Argus reduced their target price on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a report on Wednesday, May 20th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Amgen currently has a consensus rating of “Hold” and a consensus target price of $356.62.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.